Skip to main content
Q&A With Robert Foster, CEO of Hepion Pharmaceuticals [Pharm Exec]
https://www.pharmexec.com/view/q-a-with-robert-foster-ceo-of-hepion-pharmaceuticals
Hepion Striving to Repeat History by Developing its Second FDA-Approved Drug [via Benzinga]
https://www.benzinga.com/general/biotech/21/03/20282078/hepion-striving-to-repeat-history-by-developing-its-second-fda-approved-drug
Breakthrough lupus drug ‘home grown’ by Edmonton doctor approved by FDA for use [via Global News]
https://globalnews.ca/news/7670080/lupkynis-voclosporin-edmonton-drug-approved-lupus/
‘Huge potential opportunity’ for Edmonton Pharmaceutical Industry as FDA Approves Aurinia Lupus Drug [Taproot Edmonton]
https://edmonton.taproot.news/news/2021/02/03/huge-potential-opportunity-for-edmonton-pharmaceutical-industry-as-fda-approves-aurinias-lupus-drug
Hepion Pharmaceuticals employing artificial intelligence to tackle NASH [BioTuesdays]
https://hepionpharma.com/wp-content/uploads/2020/11/BioTuesdays-November-2020.pdf
Amidst a global pandemic, two biotech companies offer innovative solutions [BioTuesdays]
https://biotuesdays.com/2020/03/31/amidst-a-global-pandemic-two-biotech-companies-offer-innovative-solutions/
Breakthrough lupus drug discovered in Edmonton passes final testing phase [Global News]
https://globalnews.ca/news/6273515/lupus-drug-edmonton-discovery/
Research institute launched out of U of A attracts $25 million in investments [Edmonton Journal]
https://edmontonjournal.com/business/local-business/research-institute-launched-out-of-u-of-a-attracts-25-million-in-investments
Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH [BioTuesdays]
https://www.biotuesdays.com/features/2019/7/30/hepion-pharmaceuticals-ceo-robert-foster-discusses-crv431s-potential-in-nash
Robert Foster swinging for the fence again with Hepion Pharma [BioTuesdays]
http://www.biotuesdays.com/features/2018/11/7/robert-foster-swinging-for-the-fence-again-with-contravir-pharma
